Open AccessClinical Benefit Response in Pancreatic Cancer Trials Revisited
Author(s) -
Jürg Bernhard,
Daniel Dietrich,
Bengt Glimelius,
G. Bodoky,
Werner Scheithauer,
Richard Herrmann
Publication year - 2014
Publication title -
oncology research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.553
H-Index - 48
eISSN - 2296-5262
pISSN - 2296-5270
DOI - 10.1159/000357965
Subject(s) - medicine , hazard ratio , clinical trial , confidence interval , chemotherapy , pancreatic cancer , gastroenterology , cancer , oncology
Clinical benefit response (CBR), based on changes in pain, Karnofsky performance status, and weight, is an established palliative endpoint in trials for advanced gastrointestinal cancer. We investigated whether CBR is associated with survival, and whether CBR reflects a wide-enough range of domains to adequately capture patients' perception.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom